Evidence map›Paper›PMID 40092936›Full record

ArticleWorld journal of gastrointestinal oncology2025

Transmembrane protein 176B promotes epithelial-mesenchymal transition in colorectal cancer through inflammasome inhibition.

Wei Qian, Chong-Yi Xu, Wei Hong, Zhe-Ming Li, Dao-Gun Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wei QianDepartment of Proctology, Wenling Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Wenling 317500, Zhejiang Province, China.
Chong-Yi XuDepartment of Proctology, Wenling Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Wenling 317500, Zhejiang Province, China.
Wei HongDepartment of Proctology, Wenling Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Wenling 317500, Zhejiang Province, China.
Zhe-Ming LiCollege of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310000, Zhejiang Province, China.
Dao-Gun XuDepartment of Proctology, Wenling Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Wenling 317500, Zhejiang Province, China. 13906569665@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundActivation of the epithelial-mesenchymal transition (EMT), a pivotal process in tumor metastasis and evasion, as well as the NLRP3 inflammasome, both promote colorectal cancer (CRC) progression. Recent studies have shown that Transmembrane protein 176B (TMEM176B) regulates NLRP3 and promotes CRC malignant phenotypes.

aimTo investigate the role of TMEM176B in modulating NLRP3 inflammasome and its implications on EMT and tumor progression in CRC.

methodsCRC

resultsSilencing TMEM176B in CRC mice significantly reduced tumor metastasis, proliferation, and EMT, while activating apoptosis, NLRP3 inflammasome, and NK cell activity. Furthermore, silencing TMEM176B in co-cultured cell models inhibited cell migration and invasion, and promoted apoptosis. The interference of NLRP3 reversed these effects by modulating key proteins such as phosphorylated nuclear factor kappa B subunit 1 p65, matrix metallopeptidase 9, and transforming growth factor-β.

conclusionThis study highlights the critical role of TMEM176B/NLRP3 in CRC progression and provides a basis for targeting this axis as a novel therapeutic approach to manage CRC progression and metastasis.

Indexed as

Colorectal cancerEpithelial-mesenchymal transitionNatural killer cellPyrin domain containing 3 inflammasomeTransmembrane protein 176B

Identifiers

PMID40092936
PMCPMC11866255

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.